Cargando…

Olaratumab’s failure in soft tissue sarcoma

Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bou Zerdan, Maroun, Bidikian, Aram H, Alameh, Ibrahim, Nakib, Clara El, Assi, Hazem I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293854/ https://www.ncbi.nlm.nih.gov/pubmed/34349891 http://dx.doi.org/10.1177/20363613211034115

Ejemplares similares

Genomic Assays in Node Positive Breast Cancer Patients: A Review
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Descriptive epidemiology of soft tissue and bone sarcomas in Lebanon
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
por: Chedid, Julien, et al.
Publicado: (2022)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Outcomes of Patients with Malignancy Admitted to the Intensive Care Units: A Prospective Study
por: Assi, Hazem I., et al.
Publicado: (2021)

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
por: Moore, Donald C., et al.
Publicado: (2018)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

Oligodendroglioma: A Review of Management and Pathways
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Glioblastoma multiforme metastasizing to the skin, a case report and literature review
por: Nakib, Clara El, et al.
Publicado: (2021)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Mechanisms of Immunotoxicity: Stressors and Evaluators
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
por: Fahed, Gracia, et al.
Publicado: (2022)

A Survey on the Knowledge, Attitudes, and Practices of Lebanese Physicians Regarding Air Pollution
por: Assi, Hazem I., et al.
Publicado: (2022)

Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon
por: Atoui, Ali, et al.
Publicado: (2022)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges
por: Moubarak, Simon, et al.
Publicado: (2022)

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
por: Cornillie, Jasmien, et al.
Publicado: (2019)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Diagnostic Performance of FDG-PET/CT Scan as Compared to US-Guided FNA in Prediction of Axillary Lymph Node Involvement in Breast Cancer Patients
por: Assi, Hazem I., et al.
Publicado: (2021)

Latest updates on cellular and molecular biomarkers of gliomas
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Insights of Medical Students and Graduates Toward Electronic Learning During the COVID-19 Pandemic in Lebanon: A National Cross-Sectional Study
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience
por: Bou Akl, Imad, et al.
Publicado: (2020)

Emerging genetic biomarkers in lung adenocarcinoma
por: Barbar, Jawad, et al.
Publicado: (2022)

Multidisciplinary supportive care in systemic light chain amyloidosis
por: Maroun, Bou Zerdan, et al.
Publicado: (2022)

Carbapenemase Inhibitors: Updates on Developments in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Fertility in multiple recurrent bilateral ovarian teratomas: A case report
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Challenges of Managing Multiple Myeloma Patients with Sickle Cell Disease: A Case Report and Review of Literature
por: Zerdan, Maroun Bou, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cj8a14uemouf3fae8vodso6a36